A

Annexon Biosciences

Develops C1q inhibitor therapies

Executive Director - Regulatory Affairs

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeSan Francisco, CA, USA

About the Job

Requirements

  • A PhD or PharmD with at least 15 years of experience in Regulatory Affairs, or a BS, MS, or MSN with at least 17 years of experience.
  • Demonstrated experience leading major marketing application submissions, such as BLA, NDA, and/or MAA, including regulatory strategy development, submission execution, and regulatory review activities.
  • Ability to advise and influence executive leadership and cross-functional stakeholders through strategic regulatory guidance, effective communication of complex regulatory issues, and proactive risk assessment and mitigation.
  • Experience working directly with the FDA and EMA, with in-depth knowledge of FDA and EMA regulations and CTD/eCTD requirements.
  • Regulatory writing and review skills, with demonstrated experience authoring and overseeing high-quality regulatory submissions and Health Authority communications.
  • Understanding of the regulatory environment for biotech companies and pharmaceutical industry regulatory affairs best practices to satisfy regulatory requirements.
  • Ability to think innovatively about integrated global strategy for regulatory affairs, reimbursement, and patient care; anticipate future consequences and trends; engage regulators on new approaches; and implement new strategies for product regulatory filings.
  • Experience supporting development of biologics and/or small molecules; experience in rare disease, immunology, and/or neuroscience is preferred.
  • Organizational leadership skills and ability to collaborate with outside vendors and partner companies.

Responsibilities

  • Provide senior-level regulatory leadership for development, registration, and life-cycle management of Annexon products by collaborating with Clinical Development, Clinical Operations, Medical Affairs, CMC, and Quality to develop, coordinate, and implement global regulatory strategies and submissions, including CTAs, for new and ongoing clinical studies.
  • Lead and manage major global marketing applications, including BLAs, NDAs, and MAAs as applicable, working with internal cross-functional teams, external consultants, and vendors to drive submissions, regulatory review activities, and post-submission commitments.
  • Provide overarching strategic regulatory direction across assigned programs, including global regulatory plans, development plans and clinical study designs, risk assessments, critical issue management, and Health Authority interactions; identify regulatory risks and develop mitigation strategies.
  • Lead regulatory planning for major milestones, including INDs, CTAs, Fast Track, Breakthrough Therapy, PRIME, and Orphan Drug designations.
  • Lead high-level interactions with the FDA, EMA, and other global Health Authorities, including regulatory strategies, briefing documents, meeting preparation and leadership, and regulatory correspondence.
  • Monitor and interpret evolving global regulatory requirements, guidance, and industry trends affecting development, registration, and commercialization, and communicate implications to cross-functional stakeholders.
  • Manage day-to-day reports, submissions, and requests for Annexon products.
  • Build, mentor, develop, and lead regulatory professionals and consultants to ensure organizational excellence and successful execution of corporate objectives.
  • Perform other duties as required.

About the Company

Annexon Biosciences

Develops C1q inhibitor therapies

Annexon Biosciences develops therapies that target the classical complement pathway to treat autoimmune and neurodegenerative diseases, including eye conditions. Its main strategy is to inhibit C1q, the molecule that starts the complement cascade, with the aim of stopping disease progression at its source. The company advances therapies through clinical trials and may either commercialize them or partner with larger pharma firms to bring them to market. Revenue potential comes from product sales, licensing, and milestone payments from collaborations. Annexon’s goal is to deliver first-in-class C1q inhibitors that prevent tissue damage across diseases such as Alzheimer's, Huntington's, glaucoma, and related disorders, supported by substantial financing to push its pipeline forward.

Company size
51-200
Company stage
IPO
Headquarters
San Francisco, CA
Founded
2011

Recently Posted Jobs

Explore more opportunities at Annexon Biosciences

See more jobs